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resistant tuberculosis in China: a before-and-after study
Renzhong Li*, Yunzhou Ruan*, Qiang Sun*, Xiexiu Wang, Mingting Chen, Hui Zhang, Yanlin Zhao, Jin Zhao, Cheng Chen, Caihong Xu, Wei Su, 
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Summary
Background China has a quarter of all patients with multidrug-resistant tuberculosis (MDRTB) worldwide, but less 
than 5% are in quality treatment programmes. In a before-and-after study we aimed to assess the eﬀ ect of a 
comprehensive programme to provide universal access to diagnosis, treatment, and follow-up for MDRTB in 
four Chinese cities (population 18 million).
Methods We designated city-level hospitals in each city to diagnose and treat MDRTB. All patients with smear-positive 
pulmonary tuberculosis diagnosed in Center for Disease Control (CDC) clinics and hospitals were tested for MDRTB 
with molecular and conventional drug susceptibility tests. Patients were treated with a 24 month treatment package 
for MDRTB based on WHO guidelines. Outpatients were referred to the CDC for directly observed therapy. 
We capped total treatment package cost at US$4644. Insurance reimbursement and project subsidies limited patients’ 
expenses to 10% of charges for services within the package. We compared data from a 12 month programme period 
(2011) to those from a retrospective survey of all patients with MDRTB diagnosed in the same cities during a baseline 
period (2006–09).
Findings 243 patients were diagnosed with MDRTB or rifampicin-resistant tuberculosis during the 12 month 
programme period compared with 92 patients (equivalent to 24 per year) during the baseline period. 172 (71%) of 
243 individuals were enrolled in the programme. Time from specimen collection for resistance testing to treatment 
initiation decreased by 90% (from median 139 days [IQR 69–207] to 14 days [10–21]), the proportion of patients who 
started on appropriate drug regimen increased 2·7 times (from nine [35%] of 26 patients treated to 166 [97%] of 
172), and follow-up by the CDC after initial hospitalisation increased 24 times (from one [4%] of 23 patients to 
163 [99%] of 164 patients). 6 months after starting treatment, the proportion of patients remaining on treatment 
increased ten times (from two [8%] of 26 patients to 137 [80%] of 172), and 116 (67%) of 172 patients in the 
programme period had negative cultures or clinical–radiographic improvement. Patients’ expenses for hospital 
admission after MDRTB diagnosis decreased by 78% (from $796 to $174), reducing the ratio of patients’ expenses 
to annual household income from 17·6% to 3·5% (p<0·0001 for all comparisons between baseline and programme 
periods). However, 36 (15%) patients did not start or had to discontinue treatment in the programme period because 
of ﬁ nancial diﬃ  culties.
Interpretation This comprehensive programme substantially increased access to diagnosis, quality treatment, and 
aﬀ ordable treatment for MDRTB. The programme could help China to achieve universal access to MDRTB care but 
greater ﬁ nancial risk protection for patients is needed.
Funding Bill & Melinda Gates Foundation. 
Copyright © Li et al. Open Access article distributed under the terms of CC BY-NC-ND.
Introduction
Multidrug-resistant tuberculosis (MDRTB; deﬁ ned as 
tuberculosis resistant to both isoniazid and rifampicin) is 
a global public health problem.1 In 2009, the World 
Health Assembly (WHA) passed a resolution urging 
countries by 2015 to provide all patients with tuberculosis 
with appropriate care to prevent, diagnose, and treat the 
disease.2 In 2014, the WHA adopted this resolution as 
part of WHO’s post-2015 tuberculosis control strategy.3 
However, only a handful of countries seem on track to 
achieve universal access to MDRTB care by 2015.4 
The gap to achieve universal access is especially large in 
India and China, two countries with nearly half of the 
world’s MDRTB cases.4 Among the barriers to the scale-
up of care for MDRTB are the low number of patients 
diagnosed, poor quality of treatment, high cost of 
treatment, and inadequate ﬁ nancing for scale-up.5–8 
Unless these barriers are addressed in a comprehensive 
manner, countries are unlikely to achieve universal 
access to care by 2015.
Although China has achieved impressive reductions in 
tuberculosis prevalence and mortality during the past 
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20 years, MDRTB has become a serious issue, with more 
than 100 000 cases developing each year—roughly a 
quarter of the world’s total.9,10 In 2011, only 3% of 
estimated new MDRTB cases were diagnosed and 
reported and 2% were placed on quality treatment 
programmes.3 Many patients with tuberculosis, including 
those with MDRTB, are treated in China’s public hospital 
system. However, these patients are often given non-
standard drug regimens,11 resulting in poor treatment 
outcomes, ampliﬁ cation of drug resistance, and 
opportunities for further transmission to other 
individuals. Furthermore, in view of the low protection 
from ﬁ nancial risk resulting from illness in China,12 
patients with MDRTB almost certainly experience 
catastrophic health expenses, although this occurrence 
has not been documented.
Against this backdrop are new opportunities to improve 
access to care for MDRTB in China. New molecular 
diagnostics, which have simpliﬁ ed testing for drug 
resistance, are now available.13,14 More importantly, China’s 
health reform eﬀ orts aim to improve access to quality 
health care and increase protection from ﬁ nancial risk. 
These reforms, including expansion of health insurance 
coverage, strengthening of primary health care and public 
health, and reform of public hospitals, have the potential 
to improve quality of care for MDRTB and provide the 
ﬁ nancing needed for universal access to care. 12,15
Under the guidance of the Chinese Ministry of Health 
(now known as the National Health and Family Planning 
Commission [NHFPC]), we developed a comprehensive 
programme to provide universal access to care for 
MDRTB. In an uncontrolled before-and-after study, we 
aimed to evaluate access to diagnosis, access to quality 
treatment, and aﬀ ordability of treatment for MDRTB 
after implementation of this programme.
Methods
Study design and participants
We selected four medium-size, third-tier cities in China 
(based on their economic development) to implement 
our programme. The cities are Hohhot (Inner Mongolia, 
northern China), Kaifeng (Henan, central China), 
Lianyungang (Jiangsu, eastern China), and Yongchuan 
(Chongqing municipality, western China); further details 
are provided in the appendix. Their size, economic 
development, and geographic spread make them fairly 
representative of the situation throughout the country. 
In 2011, the four cites had a total population of 
18 million people residing in 15 urban districts and 
17 rural counties. For our programme, we grouped 
Chongqing’s Yongchuan County with four surrounding 
counties and categorised them as a city unit because 
Yongchuan is the referral centre for patients with 
tuberculosis from these other counties, and is one of the 
larger counties in Chongqing.
All cities have implemented the WHO-recommended 
directly observed therapy strategy for several years as part 
of the Chinese National Tuberculosis Control Program. 
The baseline period was from Jan 1, 2006, to Oct 31, 2009. 
The comprehensive programme started at diﬀ erent 
timepoints between Jan 1, 2011, and May 1, 2011. We 
included patients with multidrug-resistant or rifampicin-
resistant tuber culosis who were consecutively diagnosed 
in a 12-month period after the programme began in each 
of the cities.
The study was reviewed and approved by the 
Tuberculosis Operational Research Ethics Review 
Committee of the Chinese Ministry of Health. For the 
comprehensive programme, all patients signed informed 
consent before the start of treatment.
Programme
We developed a comprehensive programme to expand 
access to diagnosis, quality treatment, and aﬀ ordable 
treatment of MDRTB. Table 1 shows the details of this 
programme along with information about the previous 
programme. In each city, we designated one city-level 
hospital to be responsible for the diagnosis and treatment 
of MDRTB and other complicated forms of tuberculosis. 
We equipped the laboratories in these hospitals with 
rapid molecular testing for isoniazid and rifampicin 
resistance with the Genechip (Capitabio, Beijing, China), 
which is only approved for testing of smear-positive or 
culture-positive specimens. We trained staﬀ  in these 
hospital laboratories to do molecular tests and 
conventional drug susceptibility tests (for both ﬁ rst-line 
and second-line tuberculosis drugs).16 We established 
collaborative mechanisms between the hospital, the 
Center for Disease Control and Prevention (CDC), and 
community health-centre systems to ensure that patients, 
clinical specimens, and patients’ information were not 
lost as they moved between these systems.
We used a pre-payment mechanism to ﬁ nance a 
standard package of services for MDRTB on the basis of 
WHO guidelines (table 1).17 The total cost of the clinical 
package was capped at US$4644. We used government 
insurance funding, supplemented by project funding, to 
limit patient expenses to 10% of package costs. We also 
developed a public health package of services to better 
ensure all patients obtained diagnosis and treatment 
follow-up. These measures included transportation of 
specimens, free rapid testing for resistance, cash transfer 
to patients for transportation costs and nutritional 
supplements, and subsidy for provision of directly 
observed therapy. We provided roughly $100 000 in 
project funding to each city for this package of services 
and for laboratory equipment, laboratory renovation, 
staﬀ  training, and supervision activities.
Procedures
For the comprehensive programme, we prospectively 
collected data about patients’ characteristics, diagnosis, 
treatment, follow-up during treatment, treatment 
outcome, reason for failure to start or continue treatment, 
See Online for appendix
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hospitalisation charges, insurance payment, and 
expenses. Because HIV testing is not routinely done in 
the national tuberculosis control programme, we 
collected self-reported information about HIV status. In 
our programme cities, we also retrospectively collected 
data about all patients diagnosed with MDRTB from 
Jan 1, 2006, to Oct 31, 2009. In Hohhot, Kaifeng, and 
Lianyungang, only one hospital in each city (all at the city 
level) did drug susceptibility testing for 
Mycobacterium tuberculosis; none of the hospitals in 
Yongchuan did such testing. We reviewed laboratory 
records in the three hospitals and identiﬁ ed patients with 
tuberculosis resistant to both isoniazid and rifampicin. 
Then we reviewed available hospital records of these 
patients to collect information about diagnosis, 
treatment, and cost of hospitalisation for these patients. 
An expert committee reviewed treatment information to 
determine whether the drug regimens used were 
consistent with WHO recommendations.17 We also 
reviewed records of the local CDCs to determine if 
patients were referred to or followed up by the public 
health system. We also attempted to contact all patients 
for an in-person interview to collect information about 
treatment expenses, income, treatment follow-up, and 
outcome after hospital discharge. Additionally, we 
collected information about how the cities did diagnosis, 
treatment, patient referral and follow-up, and insurance 
reimbursement for MDRTB during 2006–09 (table 1). 
Financial data were collected in renminbi and then 
converted to US dollars for analysis. Because the 
exchange rate decreased during and between our baseline 
and programme period, we chose to use ¥6·46 to $1·00 
Baseline approach, 2006–09 Programme approach, 2011
Diagnosis
CDC No sputum culture or conventional DST done to 
diagnose drug resistance
All patients with smear-positive disease had their specimens sent to designated hospital 
for DST
Hospital Sputum culture and conventional DST done when 
patients could pay for them; culture and 
conventional DST available only in three of 
four cities
All smear-positive specimens from hospital or CDC patients had rapid molecular testing 
for rifampicin resistance done at designated city-level hospital for MDRTB diagnosis and 
treatment; culture and conventional DST for ﬁ rst-line and second-line tuberculosis 
drugs done on specimens with rifampicin resistance
System linkages None Smear-positive sputum specimens transported from CDC to hospital; hospitals notiﬁ ed 
CDC of resistance testing results
Treatment
CDC No MDRTB treatment; all patients with tuberculosis 
given standard ﬁ rst-line drug treatment (6 month 
regimen for new cases and 8 month regimen for 
previously treated cases on the basis of WHO 
recommendations)
Patients with rifampicin-resistant tuberculosis sent to designated city-level hospital for 
treatment; patients without rifampicin resistance continued standard ﬁ rst-line drug 
treatment at CDC
Hospital Second-line drugs frequently used, with or without 
documentation of drug resistance; no standard drug 
regimens or service package for MDRTB; patients 
admitted to hospital for treatment if they could pay
Patients with rifampicin-resistant tuberculosis (on the basis of rapid molecular testing) 
started on standard second-line drug regimen as part of a standard treatment package 
with a clinical algorithm*; as part of standard MDRTB treatment package, all patients 
initially admitted to hospital for treatment and discharged when stable; if conventional 
DST later showed patients to not have isoniazid resistance, treatment modiﬁ ed for 
treatment of mono-rifampicin-resistant tuberculosis*; if second-line-drug DST showed 
patient had XDRTB or pre-XDRTB, patient switched to another drug regimen*
System linkages None After receiving results of resistance testing from hospital, CDC located patients needing 
MDRTB treatment and referred them to hospital; hospital notiﬁ ed CDC about whether 
patient arrived at hospital; if patient did not show up at hospital, CDC worked with 
community or township health centres to track down patients and send them to 
hospital
Follow-up after hospitalisation
CDC No routine follow-up of patients discharged from 
hospital
Follow-up of all patients with MDRTB after discharge from hospital, then referral of 
patients to community health-care providers for DOT; follow-up of patients to ensure 
they returned to hospital for regular outpatient follow-up
Community 
health centres
Not routinely involved with follow-up of patients 
discharged from hospital
After referral from CDC, health-care providers at urban community health centres, rural 
township health centres, and village clinics followed up patients with MDRTB and 
provided DOT until treatment completion and helped to ensure patients returned to 
hospital for regular follow-up
Hospital Patients asked to return to hospital for outpatient 
follow-up; no systematic follow-up if patient did not 
return
As part of standard treatment package, patients with MDRTB returned to hospital for 
regular outpatient follow-up and treatment (every month for ﬁ rst 6 months, then every 
other month until treatment completion)
System linkages Hospitals did not routinely notify CDC at time of 
discharge and refer patients for outpatient follow-up
Hospital notiﬁ ed CDC at time of patient discharge; patients referred to CDC for 
outpatient follow-up; CDC follow-up for all patients with MDRTB who were referred at 
the time of hospital discharge; then referral of patients to community health-care 
providers for DOT; if patients did not return to hospital for regular outpatient follow-up, 
hospital contacted CDC to trace patient
(Table 1 continues on next page)
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(the average exchange rate in 2011) for all conversions to 
eliminate bias from a changing exchange rate.
Statistical analysis
We used a before-and-after analytical approach to assess 
changes in diagnosis, treatment, and aﬀ ordability of 
treatment for MDRTB. One measure of aﬀ ordability is the 
percentage of annual household income used to pay for a 
patient’s hospitalisation expenses. We used government 
data to determine the annual household income for an 
urban or rural resident in each city; income data for the 
baseline and pilot period are from 2008 and 2011, 
respectively. We used rifampicin-resistant tuberculosis 
cases in the programme period as the comparison group 
for MDRTB cases in the baseline period, because 
rifampicin-resistant and MDRTB cases were treated and 
managed the same way in our programme. We deﬁ ned 
time to MDRTB diagnosis as the number of days from 
submission of specimens for resistance testing to 
reporting of multidrug or rifampicin resistance back to 
the submitting institution. We compared continuous 
variables using Student’s t test and categorical variables 
using Pearson χ² tests or Fisher’s exact tests; two-sided 
tests with 95% CI were used in all comparisons. Data were 
entered independently by two people using EpiData 
software (version 3.1). Statistical analyses were done with 
SAS version 17.2.
Role of the funding source
Funding was provided by the governments in the four 
cities and the Bill & Melinda Gates Foundation. The 
Chinese CDC operates under the general guidance of the 
Ministry and was responsible for the design, 
implementation, and analysis of the study. The Bill & 
Melinda Gates Foundation participated in analysing the 
data and preparing the publication. RL, DPC, YR, and QS 
had complete access to all the data and had responsibility 
for the decision to submit for publication.
Results
During the baseline period (2006–09), 92 patients were 
diagnosed with MDRTB in our programme area, 
averaging 24 patients per year. Eight patients received 
treatment as outpatients only, no medical records were 
kept on them, and they were never admitted to hospital. 
The remaining 84 patients had inpatient records. We 
reviewed the inpatient medical records of 81 patients 
(three records could not be located) and interviewed 
44 patients. 79 (98%) of 81 patients had smear-positive 
disease.
In the four cities that implemented our comprehensive 
programme, 10 106 patients were diagnosed with 
pulmonary tuberculosis (including 2816 patients with 
smear-positive disease) over a 12 month period. We 
collected sputum specimens from 2365 (84%) patients 
and submitted them for rapid testing of rifampicin 
resistance. Of these specimens, 2244 (95%) had testing 
results and 243 (10%) were identiﬁ ed as rifampicin-
resistant tuberculosis. In Hohhot, only 305 (52%) of 
581 patients had sputum submitted for rapid testing, 
much lower than the 2060 (92%) of 2235 patients in the 
other three cities (p<0·0001; appendix). These missing 
data, along with insuﬃ  cient quantity of sputum 
remaining after smear examination, accounted for 
Baseline approach, 2006–09 Programme approach, 2011
(Continued from previous page)
Cost of services to patients
CDC CDC did not provide services for MDRTB Transport of sputum specimens for resistance testing and the testing itself, including 
molecular testing and DST if necessary, provided free of charge to patients
Hospital All services required fee-for-service payment by 
patients ﬁ rst, then patients sought insurance 
reimbursement; reimbursement from the 
three government insurance programmes varies but 
generally is <30% for inpatient tuberculosis services 
because second-line drugs are not reimbursable; 
very limited reimbursement for outpatient services†
A standard MDRTB treatment package negotiated with all three government insurance 
programmes provided 24 months of treatment (including inpatient and outpatient 
services and second-line drugs) capped at a total cost of US$4644†; for services in the 
MDRTB treatment package, patient payment capped at a maximum of 10% of charges 
or $464; insurance covered 40–50% of charges (exact percentages varied by 
programme and city) with remainder paid by project funding; quality of MDRTB care 
monitored by CDC; for services outside of the standard MDRTB treatment package, 
insurance coverage variable but generally about 40%, the rest paid for by patients
Other payments ·· Patients given transportation subsidy of $15·50 for each outpatient visit to hospital; 
health-care providers at community health centres, township health centres, and village 
clinics given a total of $15·50 per month per patient for providing DOT
MDRTB=multidrug-resistant tuberculosis. CDC=Center for Disease Control and Prevention. DST=drug susceptibility testing. XDRTB=extensively drug-resistant 
tuberculosis. DOT=directly observed therapy. *All patients with MDRTB started on amikacin, levoﬂ oxacin, pyrazinamide, aminosalicylic acid (also known as 
p-aminosalicylic acid), and protionamide for 6 months, then levoﬂ oxacin, pyrazinamide, aminosalicylic acid, and protionamide for 18 months. If a patient had a history 
of previous treatment with an earlier-generation quinolone (eg, oﬂ oxacin, levoﬂ oxacin) or amikacin, then moxiﬂ oxacin or capreomycin, respectively, were used instead. 
Those diagnosed with mono-rifampicin resistance were switched to treatment with amikacin, levoﬂ oxacin, pyrazinamide, isoniazid, and ethambutol for 6 months, then 
levoﬂ oxacin, pyrazinamide, isoniazid, and ethambutol for 12 months. Those diagnosed with XDRTB were switched to treatment with pyrazinamide, capreomycin, 
moxiﬂ oxacin, aminosalicylic acid, protionamide, clarithromycin, and amoxicillin-clavulanate for 12 months, then pyrazinamide, moxiﬂ oxacin, aminosalicylic acid, 
protionamide, clarithromycin, and amoxicillin-clavulanate for 18 months. †There are three government insurance schemes in China: the New Cooperative Medical 
Scheme for rural residents, the Urban Resident Basic Medical Insurance for urban residents, and the Urban Employee Basic Medical Insurance for urban employees.
 Table 1: Comparison of baseline and programme approaches to MDRTB care
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most of the 16% of patients without specimens 
submitted.
Of the 243 patients with rifampicin-resistant 
tuberculosis, 226 (93%) had drug susceptibility test 
results for isoniazid and 144 were found to have isoniazid 
resistance; therefore, 6% of individuals with sputum 
collected were documented to have MDRTB. 172 (71%) 
patients gave informed consent and were enrolled into 
our treatment programme. Among those enrolled, 
second-line results for drug susceptibility test were 
available for 163 (95%) patients. Of these individuals, 
ten (6%) had resistance to both oﬂ oxacin and kanamycin 
(extensively drug-resistant tuberculosis [XDRTB]); 
another 30 (18%) had resistance to oﬂ oxacin only, and 
seven (4%) had resistance to kanamycin only. HIV testing 
was not routinely done but each patient was asked about 
whether they were HIV positive. All patients self-reported 
as HIV negative.
Although the two patient cohorts had similar age and 
gender distributions (table 2), they had several important 
diﬀ erences. The programme cohort had signiﬁ cantly 
more rural residents (as suggested by their insurance 
source) and most were initially seen in the CDC system. 
On the basis of self-reported annual household income, 
rural patients had lower income than urban patients 
(median $330 [IQR 114–381] vs $916 [521–1118], p<0·0001) 
and CDC patients had lower income than hospital 
patients ($315 [129–383] vs $639 [186–774], p<0·0001). 
Therefore, our programme patients were probably much 
poorer than our baseline patients.
The time taken to diagnose MDRTB decreased from a 
median of 60 days (IQR 40–80) to 7 days (IQR 5–9; 
diﬀ erence 88%; table 3). For CDC patients, time to 
diagnosis included 3 days (IQR 2–5) for sputum 
specimens to be transported to the hospital.
55 (68%) of 81 patients with hospital records in the 
baseline cohort were admitted to hospital and placed on 
tuberculosis treatment after specimens were collected 
for drug susceptibility testing but before results became 
available (table 3). By the time a diagnosis of MDRTB 
became available, 13 patients were still in hospital and 
thus continued on treatment; however, 42 patients had 
already been discharged. Of the 26 patients not in 
hospital at time of diagnosis (including those discharged 
or not admitted to hospital during diagnosis), 13 were 
admitted for treatment. Therefore 26 (32%) of 
81 patients with inpatient records in the baseline cohort 
were treated after diagnosis of MDRTB. We could not 
systematically collect information about why patients 
were not treated after a diagnosis of MDRTB. 
Anecdotally, hospital workers cited inability to locate 
patients and patients’ inability to pay for treatment as 
the main reasons.
In our programme, 172 (71%) of 243 patients started 
tuberculosis treatment after a diagnosis of MDRTB or 
rifampicin-resistant tuberculosis, a proportional increase 
of 2·2 times (32% vs 71%) compared with baseline. 
Because of rapid molecular testing, no patients were 
admitted to hospital and then discharged before 
diagnosis of rifampicin resistance. 71 (29%) patients did 
not enrol in our programme because of ﬁ nancial 
Baseline 
period, 
2006–09 
(n=92)
Programme 
period, 2011 
(n=243)
p value*
Age (years) .. .. 0·64
15–29 11 (12%) 42 (17%) ..
30–44 22 (24%) 61 (25%) ..
45–59 28 (30%) 93 (38%) ..
≥60 20 (22%) 47 (19%) ..
Unknown† 11 (12%) 0 (0%) ..
Gender .. .. 0·16
Male 65 (71%) 176 (72%) ..
Female 16 (17%) 67 (28%) ..
Unknown† 11 (12%) 0 (0%) ..
Insurance .. .. <0·0001
Urban workers 26 (28%) 18 (7%) ..
Urban residents 3 (3%) 23 (9%) ..
Rural 11 (12%) 135 (56%) ..
Other 12 (13%) 6 (2%) ..
None 27 (29%) 27 (11%) ..
Unknown†‡ 13 (14%) 34 (14%) ..
Years in education .. .. ..
0 NA 33 (14%) ..
1–6 NA 57 (23%) ..
7–9 NA 85 (35%) ..
>9 NA 35 (14%) ..
Unknown‡ NA 33 (14%) ..
Employment status .. .. ..
Employed NA 45 (19%) ..
Unemployed NA 170 (70%) ..
Unknown‡ NA 28 (11%) ..
Household income per year (¥)§ .. .. ..
0–3000 NA 42 (17%) ..
3000–5000 NA 53 (22%) ..
5000–10 000 NA 35 (14%) ..
>10 000 NA 74 (30%) ..
Unknown‡ NA 39 (16%) ..
Patient category .. .. ..
New NA 67 (28%) ..
Relapse NA 69 (28%) ..
Initial treatment failure NA 16 (7%) ..
Retreatment failure or chronic 
case
NA 77 (32%) ..
Other NA 14 (6%) ..
Data are n (%) unless otherwise stated. NA=not applicable. *Statistical test for a 
categorical table. †Information unknown from the baseline cohort because 
medical records were not available from three inpatients and all eight outpatients. 
‡Information unknown from pilot cohort because these patients were not 
enrolled into the treatment programme and thus were not interviewed. 
§Equivalent to US$0–464, $465–774, $775–1548, and >$1548.
 Table 2: Patients’ characteristics
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diﬃ  culties (26 patients), being too sick or old (16 patients), 
death before treatment could start (seven patients), 
distrust of hospital (seven patients), non-qualiﬁ cation for 
programme because they were non-resident (six 
patients), miscellaneous reasons (six patients), or reasons 
not determined (three patients).
Among those who were treated after diagnosis, the 
median time from collection of specimen for resistance 
testing to treatment initiation was 139 days (IQR 69–207) 
in the baseline cohort and 14 days (IQR 10–21) in the 
programme cohort (a decrease of 90%; table 3). Among 
those treated after a diagnosis of MDRTB or rifampicin-
resistant tuberculosis, the proportion placed on an 
appropriate initial second-line drug regimen for 
tuberculosis increased by 2·7 times from 35% of 
patients (9/26) to 96% (165/172). Among all diagnosed 
patients with treatment information available 
(irrespective of treatment initiation), the proportion 
who started on an appropriate drug regimen after 
diagnosis of MDRTB or rifampicin-resistant 
tuberculosis increased by 6·2 times from 11% of 
patients (9/81) in the baseline cohort to 68% (165/243) 
in the programme cohort. Of the ten patients in the 
programme cohort with XDRTB, nine were switched to 
an eﬀ ective treatment regimen a median of 45 days 
(IQR 45–54) after starting treatment for MDRTB. 
Similarly, of the 37 patients with pre-extensive drug 
resistance—ie, those with resistance to either oﬂ oxacin 
or kanamycin, but not both—35 were switched to an 
eﬀ ective regimen for their disease a median of 55 days 
(IQR 47–64) after starting treatment for MDRTB.
At the time of discharge from hospital for MDRTB 
treatment, none of the baseline patients was referred to 
the local CDC for follow-up in the community or 
placed on directly observed therapy, although one patient 
presented himself at the CDC after discharge. By 
contrast, all 164 programme patients were referred at 
discharge, 163 (99%) were successfully followed up by 
the CDC, and 156 (95%) were placed on directly observed 
therapy in the community.
Among patients with MDRTB who started treatment, 
the proportion still on treatment 6 months after 
treatment initiation was 8% of patients (2/26) in the 
baseline cohort and 80% (137/172) in the programme 
cohort (table 3). This improvement was due to a 91% 
reduction in the proportion of patients who died or 
Baseline period, 
2006–09
Programme period, 2011 p value
Patients with a diagnosis of MDRTB or rifampicin-resistant tuberculosis 92 243 ··
CDC patients 0 152 (63%) <0·0001
Hospital patients 92 (100%) 91 (37%) <0·0001
Treatment before and after diagnosis
Patients with treatment information available* 81 243 ··
Treated while waiting for result of resistance testing 55 (68%) 0 <0·0001
Treated after diagnosis of MDRTB or rifampicin-resistant tuberculosis 26 (32%) 172 (71%) <0·0001
Initial treatment during hospitalisation after diagnosis
Patients admitted for treatment after diagnosis† 26 171 ··
Started on initial standardised treatment regimen for MDRTB‡ 9 (35%) 165 (96%) <0·0001
Treatment results during hospitalisation for treatment after diagnosis† 0·11§
Patients admitted for treatment after diagnosis 26 171 ··
Discharged on treatment 23 (88%) 164 (96%) ··
Died on treatment 0 1 (1%) ··
Discontinued treatment because of side-eﬀ ects 3 (12%) 4 (2%) ··
Discontinued treatment because of ﬁ nancial diﬃ  culties 0 2 (1%) ··
Follow-up of patients discharged on treatment
Hospitalised patients discharged on treatment 23 164 ··
Referred to CDC for follow-up 0 164 (100%) <0·0001
Successfully followed up by CDC 1 (4%) 163 (99%) <0·0001
Placed on DOT in community 0 156 (95%) <0·0001
Treatment outcome at 6 months for patients treated after diagnosis <0·0001§
Patients started on treatment after diagnosis 26 172 ··
Still on treatment 2 (8%) 137 (80%) ··
Died 6 (23%) 7 (4%) ··
Defaulted from treatment¶ 12 (46%) 3 (2%) ··
Transferred out 0 2 (1%) ··
Discontinued treatment because of side-eﬀ ects 2 (8%) 10 (6%) ··
(Table 3 continues on next page)
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defaulted from treatment (from 18 [69%] of 26 to 10 [6%] 
of 165). Among programme patients, seven (4%) died, 
ten (6%) discontinued treatment because of side-eﬀ ects, 
and eight (5%) discontinued treatment because of 
ﬁ nancial diﬃ  culties. Overall, at 6 months, 108 (63%) of 
172 programme patients had negative sputum cultures 
and eight (5%) had clinical–radiographic improvements 
even though they had no sputum. The proportion of 
patients still on treatment at 6 months was lower in 
Yongchuan than in the other three cities (29 [67%] of 
43 vs 108 [84%] of 129, p=0·022; appendix).
Among all programme patients diagnosed with 
rifampicin resistance or MDRTB (irrespective of whether 
they were treated or not), 36 (15%) did not start or could 
not continue treatment because of ﬁ nancial diﬃ  culties 
and 15 (6%) died within 6 months. However, the actual 
proportion of deaths might be higher because another 
16 patients were too sick or old to start treatment.
Our programme eliminated the need for hospital 
admission while waiting for results of resistance testing. 
During the baseline period, median out-of-pocket patient 
expenses for this hospitalisation were $846, which was 
21% of the annual household income in our programme 
area (table 4). Using 10% and 20% of annual household 
income as the threshold for catastrophic health 
expenses,18 we calculated that 80% (44/55) and 38% 
(21/55) of patients, respectively, had catastrophic health 
expenses for this hospital admission alone.
Our programme also reduced the median cost of 
hospital admission after diagnosis of MDRTB by 30% 
($1135 to $800; table 4). Because of increased insurance 
reimbursement and project subsidy, patients’ out-of-
pocket expenses for this hospital admission were only 
$174, which was 3·5% of the annual household income 
during the programme period. Our programme reduced 
the proportion of patients with catastrophic health 
expenses for this hospital admission from 58% (15/26) 
to 6% (10/171; p<0·0001) when 10% of household 
income was used as the catastrophic threshold,18 and 
from 42% (11/26) to 1% (2/171; p<0·0001) when the 
20% threshold was used.19 Overall, 68 baseline patients 
were admitted to hospital during diagnosis, after 
diagnosis, or both. Of these patients, 56 (82%) had 
catastrophic expenses from these hospital admissions 
for the 10% threshold and 33 (49%) had catastrophic 
health expenses for the 20% threshold.
Because patients’ actual household incomes might be 
lower than average among residents in their cities, we 
Baseline period, 
2006–09
Programme period, 2011 p value
(Continued from previous page)
Discontinued treatment because of ﬁ nancial diﬃ  culties 0 8 (5%) ··
Discontinued for other reasons 4 (15%) 5 (3%) ··
Sputum culture conversion at 6 months
Patients started on treatment after diagnosis NA 172 ··
Culture-negative NA 108 (63%) ··
Culture-positive NA 18 (10%) ··
No sputum|| NA 8 (5%) ··
Sputum not checked NA 3 (2%) ··
Days from specimen collection for resistance testing to diagnosis**
CDC patients NA 8 (6–11) ··
Hospital patients 60 (40–80) 6 (3–8) <0·0001
All patients 60 (40–80) 7 (5–9) <0·0001
Days from diagnosis to start of treatment††
CDC patients NA 7 (5–12) ··
Hospital patients 57·5 (0–113) 4 (2–11) <0·0001
All patients 57·5 (0–113) 6 (3–12) <0·0001
Days from specimen collection for resistance testing to start of treatment††
CDC patients NA 14 (11–21) ··
Hospital patients 139 (69–207) 12 (8–21) <0·0001
All patients 139 (69–207) 14 (10–21) <0·0001
Data are n, n (%), or median (IQR). NA=not applicable. CDC=Center for Disease Control and Prevention. DOT=directly observed therapy. MDRTB=multidrug-resistant 
tuberculosis. *Of the 92 baseline patients, treatment information unavailable from three inpatients and eight patients who were treated only as outpatients. †Of the 
172 patients treated during the programme period, one was treated exclusively as an outpatient. ‡Pending results from drug susceptibility testing for second-line drugs, 
patients started on an initial empiric drug regimen for MDRTB treatment that is consistent with WHO guidelines. §p value for all percentage comparisons. ¶Lost to follow-up 
and interrupted treatment for at least two consecutive months. ||Seven patients had both clinical and chest radiographic improvement; one had no change in chest 
radiograph. **Information about baseline patients is based on 55 patients with complete information on date when specimen was sent for drug susceptibility testing. 
††For patients started on treatment after diagnosis of MDRTB or rifampicin-resistant tuberculosis. 
Table 3: Diagnosis, treatment, and follow-up of patients with MDRTB or rifampicin-resistant tuberculosis
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reanalysed the percentage of patients with catastrophic 
health expenses using data for patients’ self-reported 
household income. For the hospital admission after a 
diagnosis of MDRTB, 95 (57%) of our programme 
patients had catastrophic health expenses (using the 10% 
threshold). Although self-reported income data are 
diﬃ  cult to verify, these results suggest the use of average 
household income among all residents could lead to 
underestimation of those with catastrophic expenses.
Of the total hospitalisation charges, $619 (77%) was for 
services within the MDRTB treatment package. For 
charges within the package, patients paid only $65 (11%) 
and insurance paid $278 (45%). For charges outside of 
the MDRTB treatment package, patients paid an average 
of $110 (61%). Overall, 68% of all patient expenses were 
for services outside of the MDRTB treatment package. 
We also reanalysed the ﬁ nancial data using only patients 
from the three cities that had baseline patients with 
MDRTB. All of the reductions documented in the four-
city analysis were greater in the three-city analysis.
Discussion
This before-and-after analysis of a comprehensive 
programme shows how China can provide universal 
access to MDRTB care by simultaneously expanding 
access to diagnosis, quality treatment, and more 
aﬀ ordable care of MDRTB. To our knowledge it is the 
ﬁ rst programme to demonstrate how the key barriers to 
MDRTB care can be eﬀ ectively addressed with new 
molecular diagnostics, quality treatment, system 
linkages to ensure continuity of care, and ﬁ nancing by 
government insurance schemes (panel). Our results are 
particularly applicable to middle-income countries that 
have most of the global burden of MDRTB but need to 
rely on domestic resources to scale-up care for the 
disease.34,35
Our comprehensive programme successfully expanded 
access to the diagnosis of smear-positive MDRTB. In a 
1 year period, the programme successfully tested 84% of 
all smear-positive patients with tuberculosis in our 
programme area for MDRTB or rifampicin resistance. 
As a result, the programme identiﬁ ed ten times more 
patients needing treatment for MDRTB than were 
identiﬁ ed during the baseline period, including many 
more poor rural patients who would not have been 
diagnosed without the programme. The programme 
would have identiﬁ ed even more patients if not for a 
major problem with submission of sputum specimens in 
one city and insuﬃ  cient remaining quantity of sputum 
after sputum examination in some patients. These 
problems can be addressed by use of a diagnostic such as 
Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA) to 
replace smear examination in diagnosis of tuberculosis 
and provide testing of rifampicin resistance—all with the 
same specimen—at a county-level or district-level 
laboratory. In our analysis we grouped patients with 
rifampicin-resistant tuberculosis with those with 
MDRTB because they need the same treatment. By 
providing free testing of resistance to all CDC patients, 
our programme increased access to diagnosis and 
eventual treatment of MDRTB for poor, rural patients 
who would otherwise not have made it to a city-level 
hospital for diagnosis.
Our programme substantially reduced the time to 
diagnosis of and treatment initiation for smear-positive 
MDRTB. Reduction of time to treatment initiation is 
important because a high proportion of patients with 
MDRTB are lost to follow-up or die while waiting for 
their diagnosis, especially in high-HIV-prevalence 
settings.36–38 The programme reduced the time to 
diagnose MDRTB by nearly 90%, from 57 days to 7 days. 
The programme also reduced the time to treatment 
initiation by 90%, from 139 days to 14 days. As a result, 
Baseline period, 
2006–09
Programme 
period, 2011
p value
Hospitalisation pending results of resistance testing
Number of patients 55 ·· ··
Average charges per patient (US$) 1207 (814–1421) ·· ··
Average number of hospital days per patient 35·6 (22·5–40·5) ·· ··
Average charges per hospital day ($) 34 (29–44) ·· ··
Payment for hospitalisation ·· ··
Average insurance payment ($) 361 (244–425)* ·· ··
Average insurance payment as a 
proportion of total payment
29·9% ·· ··
Average patient out-of-pocket payment 
($)
846 (571–996) ·· ··
Average patient out-of-pocket payment 
as a proportion of total payment
70·1% ·· ··
Patient payment as a proportion of annual 
household income†
21·0% (10·7–26·9) ·· ··
Hospitalisation for MDRTB treatment after diagnosis
Number of patients 26 171 ··
Average charges per patient ($) 1135 (351–1612) 800 (363–993) 0·034
Average number of hospital days per patient 30·5 (8–45) 39 (23–51·5) 0·082
Average charges per hospital day ($) 37 (26–51) 20 (12–25) 0·001
Payment for hospitalisation
Average insurance payment ($) 339 (105–482)* 350 (126–463) <0·0001
Average insurance payment as a 
proportion of total payment
29·9% 43·8%
Average patient out-of-pocket payment 
($)
796 (246–1130) 174 (57–174) <0·0001
Average patient out-of-pocket payment 
as a proportion of total payment
70·1% 21·8%
Average project payment ($) ·· 275 (131–346) ··
Average project payment as a proportion 
of total payment
·· 34·4% ··
Patient payment as a proportion of annual 
household income†
17·6% (6·2–26·8) 3·5% (1·1–3·9) <0·0001
Data are median (IQR) unless otherwise stated. MDRTB=multidrug-resistant tuberculosis. *Percent of hospitalisation 
charges paid by insurance comes from the median percentage ascertained from interview of 44 patients in baseline 
period. †Each patient’s payment for the hospitalisation is divided by the average annual household income of an urban 
or rural resident in each city for each time period, which is then averaged for all patients.
 Table 4: Hospitalisation charges, payment, and ﬁ nancial burden on patients
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the proportion of patients who started treatment after 
diagnosis more than doubled.
To our knowledge, ﬁ ndings from only two studies 
have shown the time to treatment initiation when a 
molecular diagnostic was used to diagnose MDRTB.29,30 
The investigators reported a treatment delay of 
50–55 days for patients with smear-positive MDRTB 
and attributed it to both laboratory and system delays. 
The time to treatment initiation for MDRTB in our 
programme was substantially shorter than the delay 
reported in these studies. The availability of molecular 
testing partly accounted for this decrease. But equally 
important was our eﬀ ort to implement new linkage 
mechanisms between the CDC and the hospital 
systems, which improved, for example, specimen 
transportation, reporting of test results, and CDC 
referral of patients with MDRTB to hospitals. Although 
simple, these system linkages were very important to 
the success of our programme.
Our comprehensive programme also expanded access 
to quality treatment for MDRTB. Among those started on 
treatment, our programme increased the proportion who 
started on an initial WHO-recommended drug regimen 
from a third to nearly all patients. If a programme 
expands access to treatment but initial treatment quality 
is poor, both patients and the public at large could be 
harmed by the development of more serious forms of 
drug-resistant tuberculosis, such as XDRTB.39,40 Through 
the use of a clinical pathway, with CDC staﬀ  monitoring 
adherence to clinical protocols, our programme largely 
eliminated the use of improper initial treatments. 
Additionally, we used drug susceptibility testing to 
identify patients with XDRTB and eventually started 
them on appropriate treatment.
Improvement in treatment quality extended to follow-
up in the community. At the time of hospital discharge, 
our programme referred all patients to the local CDC for 
outpatient follow-up and directly observed therapy. Such 
referrals and follow-up are examples of eﬀ ective system 
linkages, which were not in place during the baseline 
period. In a meta-analysis, directly observed therapy and 
follow-up by a community health worker were associated 
with decreased risk of defaulting from treatment for 
MDRTB.20 We also provided transportation and food 
subsidies. Thus, our programme incorporated several 
best practices of community care for patients with 
tuberculosis.
Because of improved treatment quality, our programme 
substantially improved treatment outcome at the end of 
6 months. The proportion of patients still on treatment at 
6 months increased nine times, mainly due to a 
90% reduction in the proportion of patients who 
defaulted or died. Only 2% of our patients had defaulted 
by 6 months, which compares favourably with the 15% 
proportion of treatment default reported in other 
treatment programmes for MDRTB (even though these 
programmes measured default over 18–24 months of 
treatment).20 Overall, nearly 70% of our patients had 
documented improvement by 6 months after starting 
treatment, similar to other quality treatment programmes 
for MDRTB globally.21,22
Before our programme, out-of-pocket expenses for 
MDRTB treatment were very high. While awaiting 
results of conventional drug susceptibility test, most 
baseline patients with MDRTB were admitted to 
hospital for a month and at discharge paid more than 
$800 in medical expenses. When a conﬁ rmed diagnosis 
of MDRTB became available another month later, only a 
third of these patients received MDRTB treatment and 
were admitted to hospital; they paid a further $800 in 
medical expenses. The out-of-pocket expenses for each 
of these hospitalisations were roughly 20% of the 
annual household income of local residents. When a 
household’s health expenses reach 10% of its annual 
income, the World Bank considers this catastrophic.18 
Among baseline patients who were hospitalised during 
the diagnostic or early treatment period, or both, over 
Panel: Research in context
Systematic review
We reviewed the scientiﬁ c literature on multidrug-resistant tuberculosis (MDRTB) and 
molecular diagnosis, treatment, and aﬀ ordability of care. We used as our starting point 
ﬁ ve systematic reviews and meta-analyses on molecular diagnostics for MDRTB published 
between 2008 and 2014, and ﬁ ve systematic reviews and meta-analyses on MDRTB 
treatment published between 2009 and 2013.13,20–28 We supplemented these by searching 
PubMed with the terms “multidrug-resistant tuberculosis” for English-language articles 
published from Jan 1, 2010, to Jan 31, 2014. We looked for articles relevant to our topics 
of interest. Additionally, using PubMed, we looked for English-language articles published 
from Jan 1, 2000, to Jan 31, 2014, containing the terms “multidrug-resistant tuberculosis” 
and any of the following: “insurance”, “ﬁ nancial protection”, “aﬀ ordability”, “patient 
cost”, “economic burden”, or “universal access”.
Interpretation
There are many publications about molecular testing for drug-resistant tuberculosis, but 
they exclusively describe test performance in laboratory or ﬁ eld conditions. There are 
also publications comparing time to diagnosis for molecular versus conventional drug 
susceptibility tests. However, we found only two studies that compared time to 
treatment initiation for MDRTB for cases diagnosed with molecular versus conventional 
drug susceptibility tests.29,30 There are many publications on MDRTB treatment. All of 
them are observational studies and reported treatment outcome for patient cohorts in a 
variety of settings. We did not ﬁ nd any publications that compared treatment outcome 
for MDRTB diagnosed witht molecular versus conventional drug susceptibility tests. 
There are several descriptions of successful programme models for MDRTB. Most 
publications came from programme models in Russia, Peru, and the Philippines.31–33 These 
programmes were initially called directly observed therapy, short-course plus and later 
changed to be known as programmatic management of drug-resistant tuberculosis 
(PMDT). We did not ﬁ nd any publications on use of insurance funding for or aﬀ ordability 
of MDRTB treatment. Many of the programme components believed to be important for 
a successful PMDT have been reported previously. However, very few studies quantiﬁ ed 
the eﬀ ectiveness of system linkages such as patient referral or follow-up as in our study. 
In addition, our study is the ﬁ rst to report the eﬀ ects of molecular diagnostics on patient 
outcome and ﬁ nancial burden, and also the ﬁ rst to describe the use of a pre-payment 
mechanism for MDRTB.
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80% had catastrophic health expenses. Even if one uses 
20% of household income as a more conservative 
threshold,19 half of these patients had catastrophic 
expenses.
Our comprehensive programme successfully reduced 
patient expenses for MDRTB treatment and made 
treatment more aﬀ ordable. Through the use of rapid 
resistance testing and improved referral between the 
CDC and hospital systems, our programme eliminated 
the need for hospitalisation pending results of 
resistance testing, thus reducing patient expenses. Our 
programme also reduced the patient expenses for 
treatment after MDRTB diagnosis. We achieved this by 
using a standard MDRTB treatment package of services 
to control medical cost, capping the charges for the 
2-year treatment course at $4644, and reducing patient 
expenses to 10% of the medical charges for the 
treatment package through increased insurance 
funding and project funding. As a result, the patient 
expenses for hospitalisation after MDRTB diagnosis 
were reduced to $174, which was only 3·5% of the 
annual household income for residents in our study 
area. This greatly reduced the percentage of patients 
with catastrophic health expenses for initial hospital 
treatment of MDRTB.
Although we improved the aﬀ ordability of MDRTB 
treatment, it is unlikely that our programme eliminated 
catastrophic health expenses for those with MDRTB. An 
important ﬁ nding in our study was that 15% of patients 
in our programme could not start or had to discontinue 
MDRTB treatment because of ﬁ nancial diﬃ  culties. Our 
analysis of patient expenses for MDRTB did not include 
expenses for treatment of comorbidities and non-
medical costs of illness such as lost income and 
transportation cost.41 Additionally, many patients had 
already incurred substantial expenses for unsuccessful 
treatments in the past. Therefore the cumulative 
expenses incurred could have reached catastrophic level 
for many more patients. Furthermore, we used the 
average household income of local residents to calculate 
catastrophic health expenses when patients with 
tuberculosis are generally poorer. Therefore we could 
have underestimated the proportion of patients with 
catastrophic health expenses.
On the basis of results from this programme, the 
NHFPC has secured funding to scale-up diﬀ erent 
aspects of this programme nationwide, thus enhancing 
its sustainability. First, free MDRTB testing with 
molecular diagnostics will be expanded to more than 
30% of Chinese cities in 2014. Second, our standard 
package of MDRTB care has been adopted for 
nationwide use. Third, the NHFPC has already 
designated MDRTB as one of eight priority diseases 
eligible for 70% reimbursement in the government’s 
rural insurance programme. However, because our 
results showed that insurance reimbursement for 
MDRTB should exceed 90%, the NHFPC has tapped 
into the country’s social protection fund for the poorest 
segment of the population and is using it to provide 
additional ﬁ nancial assistance for the poorest patients. 
Nevertheless, more funding will be needed to ensure 
the sustainability of this programme, including, for 
instance, funding for training, laboratory renovation, 
and cash transfer payments to patients for transportation 
and nutrition supplements.
Our study has important lessons for other countries 
with high MDRTB burden as they seek to expand access 
to MDRTB care. First, our programme demonstrated 
that the beneﬁ ts of molecular diagnostics for MDRTB 
extended beyond making a more rapid diagnosis. 
Molecular testing also shortened the time to treatment 
initiation, reduced loss to follow-up after diagnosis, and 
increased aﬀ ordability of treatment. Second, an eﬀ ective 
MDRTB programme should include government 
funding for public health elements that can ensure 
universal diagnosis, system linkages, and continuity of 
care. In our programme, these elements included 
specimen transport, free testing for tuberculosis 
resistance, following up of patients in the community, 
directly observed therapy, and cash transfer to patients 
for transportation fees and nutritional supplements. 
Governments should separately fund these items as a 
form of public good. Third, the use of a pre-payment 
mechanism to ﬁ nance MDRTB treatment can facilitate 
access by minimising medical expenses at the point of 
care and reduce catastrophic health expenses. To our 
knowledge this programme is the ﬁ rst to describe how a 
government insurance scheme can ﬁ nance an eﬀ ective 
MDRTB treatment programme. However, our use of 
initial hospitalisation for all patients with MDRTB may 
not apply to all settings. China has suﬃ  cient hospital 
beds to accommodate a scale-up of this programme, but 
other countries might not.
Our study has several limitations. First, the programme 
identiﬁ ed smear-positive but not smear-negative MDRTB 
cases because the Genechip diagnostic can only be used 
in smear-positive or culture-positive specimens. 
However, our programme has all the other elements 
needed to expand treatment to these smear-negative 
MDRTB cases. For instance, the current insurance 
reimbursement for MDRTB is not restricted to 
individuals with smear-positive disease, nor are any of 
the other programme activities such as initiation of a 
WHO-recommended treatment regimen or successful 
referral for follow-up in the community. Therefore, once 
a reliable rapid test to detect rifampicin resistance in 
smear-negative specimens is available in China, our 
programme can easily expand to cover all MDRTB cases. 
Second, the use of a before-and-after study design means 
that temporal improvements in quality of health services 
or the involvement of researchers (the so-called 
Hawthorne eﬀ ect) could have resulted in some of the 
improvements in this study; our study also did not 
include contemporaneous controls. Third, the amount 
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and quality of our baseline data were restricted by the 
information available in hospital records, by diﬃ  culty in 
locating patients for interview, and by recall bias. For 
example, HIV-positivity could have been biased by self-
report. However, better-quality data are unlikely to 
change our key ﬁ ndings and conclusions. Fourth, there 
was substantial delay in provision of patients with 
XDRTB with appropriate treatment. In the future, the 
availability of rapid resistance testing to other key second-
line tuberculosis drugs will ensure that those with 
XDRTB in our programme are started on appropriate 
treatment much earlier.
Finally, the results of this programme are striking 
when viewed from a population-based perspective. 
Before our programme, in a population of 18 million 
people, we identiﬁ ed only two patients with MDRTB 
over a period of nearly 4 years who were properly 
diagnosed, started on appropriate treatment, and still 
on treatment 6 months later—an average of less than 
one patient per year. Our programme increased the 
number of such patients more than 100 times. On the 
one hand, this scenario provides a glimpse into why 
MDRTB is such a serious public health problem in 
China. On the other, it shows the potential of our 
comprehensive programme to substantially reduce the 
morbidity, mortality, and transmission of MDRTB in a 
country with one of the largest MDRTB epidemics in 
the world.
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